AAN 2023 | Safety and efficacy of microburst VNS

Cornelia Drees, MD, Mayo Clinic, Phoenix, AZ, discusses the clinical impact of microburst vagus nerve stimulation (µVNS) for the treatment of drug-resistant epilepsy. An early feasibility study found that responder rates were above 60% after 12 months, and seizure severity decreased in 70% of patients. Any adverse effects were comparable to those of standard VNS. This study was ended early due to COVID-19 but supports the use of µVNS for the treatment of drug-resistant epilepsy. Future studies should explore the use of fMRI for the generation of individually titrated stimulation settings.
This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.